Drugs / VENT 02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06822517 | Mar → Oct 2025 | Parkinson disease | Ventus Therapeutics U.S., Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VENT 02 | “evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate...” NCT06822517 ↗ |
| Action | Inhibit | “NLRP3 Inhibitor” NCT06822517 ↗ |
| Route | Oral | “administered orally at 1 dose level twice daily (BID) over 28 days” NCT06822517 ↗ |
| Target | NLRP3 | “NLRP3 Inhibitor” NCT06822517 ↗ |